Ferring Pharmaceuticals Ltd

Drayton Hall, Church Road, West Drayton, UB7 7PS, UK
Telephone: +44 (0)844 931 0050
Fax: +44 (0)844 931 0051
WWW: http://www.ferring.co.uk
Medical Information Direct Line: +44 (0)844 931 0054
Medical Information e-mail: medical@ferring.com
Medical Information Fax: +44 (0)844 931 0051

Summary of Product Characteristics last updated on the eMC: 21/03/2005
SPC Tractocile 7.5 mg/ml Concentrate for Solution for Infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 21/03/2005 and displayed until Current
Reasons for adding or updating:
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 3 - pharmaceutical form
  • Change to section 4.1 - Therapeutic Indications
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5 - Pharmacological Properties
  • Change to section 6.1 - List of Excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 9 - Date of Renewal of Authorisation
  • Change to section 10 (date of (partial) revision of the text
Updated on 22/09/2004 and displayed until 21/03/2005
Reasons for adding or updating:
  • Addition of Legal Category
Updated on 02/07/2004 and displayed until 22/09/2004
Reasons for adding or updating:
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 5.3 - Preclinical Safety Data
Updated on 10/06/2004 and displayed until 02/07/2004
Reasons for adding or updating:
  • Removal of Black Triangle
Updated on 11/03/2003 and displayed until 10/06/2004
Reasons for adding or updating:
  • Change to section 5.1 - Pharmacodynamic Properties
Updated on 28/08/2002 and displayed until 11/03/2003
Reasons for adding or updating:
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
Updated on 22/08/2002 and displayed until 28/08/2002
Reasons for adding or updating:
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
Updated on 17/08/2001 and displayed until 22/08/2002
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 22/03/2001 and displayed until 17/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/02/2001 and displayed until 22/03/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   atosiban